Skip to main content
Evidence Snapshot

Prostacyclin receptor

CHEMBL1995 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:00Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1995
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prostacyclin receptor as ChEMBL target CHEMBL1995, mapped to UniProt P43119. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prostacyclin receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1995
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P43119
Prostacyclin receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Prostacyclin receptor matters

As of 2026-09-14

Prostacyclin receptor is reviewed as Prostacyclin receptor (UniProt P43119); Prostacyclin receptor shows approved-linked disease relevance led by pulmonary arterial hypertension. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 12 approved drugs, 961 compounds, and 155 assays, with lead potency reaching pChEMBL 9.4.

Disease context
pulmonary arterial hypertension

Prostacyclin receptor shows approved-linked disease relevance led by pulmonary arterial hypertension. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ESUBERAPROST, ILOPROST, ILOPROST TROMETHAMINE.

Start review with pulmonary arterial hypertension because it currently carries approved-linked support. Linked drugs include ESUBERAPROST, ILOPROST, ILOPROST TROMETHAMINE, RALINEPAG. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 8 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 12 approved drugs, 961 compounds, and 155 assays for this target. The dominant activity type is EC50. CHEMBL494 is the current potency anchor at pChEMBL 9.4.

Use CHEMBL494 as the tractability anchor when discussing potency (pChEMBL 9.4).

Activity source · ChEMBL 36 via Core Engine
12 approved pChEMBL 9.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Prostacyclin receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P43119, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why pulmonary arterial hypertension is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

961
Total Compounds
155
Total Assays
12
Approved Drugs
IC50: 246.0, KI: 319.0, EC50: 341.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL494
 9.4 EC50 Approved
No preferred name
CHEMBL495
 8.7 EC50 Approved
No preferred name
CHEMBL1237119
 8.7 EC50 Approved
No preferred name
CHEMBL6019262
 8.7 EC50 —
No preferred name
CHEMBL3301604
 8.6 EC50 Clinical

Approved Drugs

Structure Compound First Approval
SELEXIPAG
CHEMBL238804
 2015
ILOPROST
CHEMBL494
 2003
TREPROSTINIL
CHEMBL1237119
 2002
ALPROSTADIL
CHEMBL495
 1981
DINOPROSTONE
CHEMBL548
 1977
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:00Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1995